SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event
reported): December 15, 2017
Ohr Pharmaceutical, Inc.
Name of Registrant as Specified in Its Charter)
or Other Jurisdiction
Third Avenue, 11th Floor, New York, NY
of Principal Executive Offices)
Telephone Number, Including Area Code)
Name or Former Address, if Changed Since Last Report)
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17
CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
growth company ☐
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Item 8.01. Other Events.
As previously reported, on April 6, 2017, the Nasdaq
Stock Market (“Nasdaq”) notified Ohr Pharmaceutical, Inc. (the “Company”) that its common stock failed
to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Listing Rules of Nasdaq.
On December 15, 2017, the Company received notice from Nasdaq confirming that for the last 10 consecutive business days, from
December 1, 2017 to December 14, 2017, the closing bid price of the Company’s common stock has been at $1.00 per share or
greater. Accordingly, Nasdaq has determined that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2).
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.